Flexion (FLXN) Could Trade to $34 Following Data - RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Flexion Therapeutics (FLXN) Fair Value Target Raised to $33 at Janney Capital
February 17, 2016 7:30 AM ESTJanney Capital analyst Ken Trbovich raised his fair value estimates on Buy-rated Flexion Therapeutics (NASDAQ: FLXN) to $33.00 (from $27.00) after the company reported its Phase 3 study of Zilretta achieved its primary endpoint with highly significant results.
:We see this as a major... More
Flexion Therapeutics (FLXN) Announces Zilretta Phase 3 Met Primary Endpoint in Knee Osteoarthritis
February 16, 2016 4:02 PM ESTFlexion Therapeutics, Inc. (Nasdaq: FLXN) reported that the Phase 3 clinical trial for its lead drug candidate Zilretta (also known as FX006) met its primary endpoint at week 12, demonstrating highly significant (p... More
